EYLONGIR Trademark

Trademark Overview

On Wednesday, February 9, 2022, a trademark application was filed for EYLONGIR with the United States Patent and Trademark Office. The USPTO has given the EYLONGIR trademark a serial number of 97260195. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Wednesday, February 26, 2025. This trademark is owned by Regeneron Pharmaceuticals, Inc.. The EYLONGIR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of ophthalmological diseases and disorders
eylongir

General Information

Serial Number97260195
Word MarkEYLONGIR
Filing DateWednesday, February 9, 2022
Status733 - FOURTH EXTENSION - GRANTED
Status DateWednesday, February 26, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of ophthalmological diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 15, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRegeneron Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591

Trademark Events

Event DateEvent Description
Saturday, February 12, 2022NEW APPLICATION ENTERED
Tuesday, February 15, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 14, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 14, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 14, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, September 26, 2022ASSIGNED TO EXAMINER
Monday, September 26, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 12, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 1, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 1, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 27, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, May 26, 2023SOU TEAS EXTENSION RECEIVED
Friday, May 26, 2023SOU EXTENSION 1 FILED
Friday, May 26, 2023SOU EXTENSION 1 GRANTED
Tuesday, May 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, January 27, 2024SOU EXTENSION 2 GRANTED
Thursday, December 14, 2023SOU TEAS EXTENSION RECEIVED
Thursday, December 14, 2023SOU EXTENSION 2 FILED
Thursday, January 4, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, January 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 29, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 29, 2024SOU EXTENSION 3 FILED
Wednesday, May 29, 2024SOU EXTENSION 3 GRANTED
Friday, December 13, 2024SOU EXTENSION 4 FILED
Wednesday, February 26, 2025SOU EXTENSION 4 GRANTED
Thursday, February 27, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 13, 2024SOU TEAS EXTENSION RECEIVED

Related Keywords

eylongir diseases disorders ophthalmological treatment preparations pharmaceutical